Published in J Antimicrob Chemother on April 11, 2011
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2013) 1.07
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2012) 1.02
Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis. Antimicrob Agents Chemother (2012) 0.90
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother (2013) 0.89
Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother (2014) 0.86
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother (2013) 0.85
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol (2004) 2.15
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Polymyxins: wisdom does not always come with age. Clin Infect Dis (2013) 2.13
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol (2005) 1.98
Ca(2+)/calmodulin regulates salicylic-acid-mediated plant immunity. Nature (2009) 1.97
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol (2012) 1.93
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol (2003) 1.73
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis (2008) 1.64
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med (2002) 1.60
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58
Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol (2008) 1.58
Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis (2008) 1.57
Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis (2007) 1.54
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood (2004) 1.51
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51
The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis (2011) 1.49
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis (2013) 1.49
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2002) 1.47
Aminopeptidase N inhibitors and SARS. Lancet (2003) 1.47
Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis (2005) 1.47
Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis (2006) 1.46
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis (2006) 1.46
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis (2009) 1.44
Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis (2014) 1.42
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood (2004) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Detection of gliotoxin in experimental and human aspergillosis. Infect Immun (2005) 1.38
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother (2002) 1.36
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Isogenic auxotrophic mutant strains in the Aspergillus fumigatus genome reference strain AF293. Arch Microbiol (2004) 1.34
Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis (2009) 1.33
Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol (2008) 1.33
Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect (2010) 1.32
Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis (2006) 1.31
Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood (2009) 1.28
Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One (2010) 1.25
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect (2002) 1.23
Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis (2012) 1.22
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 1.21
Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol (2010) 1.21
Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer (2004) 1.20
Epidemiology and treatment of mucormycosis. Future Microbiol (2013) 1.18
Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol (2006) 1.17
Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol (2005) 1.17
Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. J Neurosurg (2003) 1.16
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses (2013) 1.15
Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis (2005) 1.13
Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother (2008) 1.13
Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother (2006) 1.13
Risk factors for mortality in patients with mucormycosis. Med Mycol (2012) 1.13